COX-2 inhibitors with the aim of improving their pharmacokinetic properties. As expected, the deuterated compounds retained potency and selectivity for COX-2. The new molecules possess improved pharmacokinetic profiles in rats compared to their nondeuterated congeners. Most importantly, the new compounds showed pharmacodynamic efficacy in several murine models of inflammation and pain. The benzopyran derivatives
我们设计了一系列专门
氘化的苯并
吡喃类似物作为新的COX-2
抑制剂,旨在改善其药代动力学特性。如预期的那样,
氘代化合物保留了对COX-2的效力和选择性。与它们的非
氘代同类物相比,新分子在大鼠中具有改善的药代动力学特征。最重要的是,新化合物在几种小鼠炎症和疼痛模型中均显示出药效学功效。苯并
吡喃衍
生物被分离成它们的对映异构体,并且发现该活性与S-异构体有关。为了简化所需S异构体的合成,开发了有机催化的不对称多米诺oxa-Michael /羟醛缩合反应用于制备。